Authors: M. Masserini, M. Gregori, E. Salvati, F. Re, M. Masserini
Affilation: University Milano Bicocca, Italy
Pages: 339 - 342
Keywords: Alzheimer’s disease, blood brain barrier, nanoparticles
NAD project (large cooperative; 19 partners, funded by the E.C.) is aiming to the therapy and diagnosis, even combined, of Alzheimer Disease, by synthesis of multiple-functionalized nanoparticles, able to bind, detect and remove Abeta from the brain and from the blood. NAD partners have realized different types of NPs (liposomes, SLN, PHDCA) specifically functionalized to bind Aβ with high affinity and to cross the blood brain barrier in vitro. Treatment of animal models of the disease (TG mice) suggest that double-functionalized NP can decrease the levels of Abeta in the blood and the content of Abeta in the brain. More than 40 papers have been published and 4 patents filed.
Nanotech Conference Proceedings are now published in the TechConnect Briefs